1. Introduction to FGFR Inhibitors
1.1 Overview
1.2 Evolution of FGFR Inhibitors

2. FGFR Inhibitors - Mechanism of Action

3. Role of FGFR Inhibitors in Cancer Therapy
3.1 AZD4547
3.2 E7090
3.3 Debio 1347
3.4 Futibatinib
3.5 Rogaratinib
3.6 Derazantinib
3.7 RLY-4008
3.8 CPL304110

4. Global FGFR Inhibitor Market Analysis
4.1 Current Market Scenario
4.2 Future Market Opportunity

5. Global FGFR Inhibitors Market Opportunity by Region
5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World

6. Global FGFR Inhibitors Market Opportunity by Cancer
6.1 Cholangiocarcinoma
6.2 Urothelial Carcinoma
6.3 Lymphoma
6.4 Lung Cancer

7. Balversa - First Approved FGFR Inhibitor 2019
7.1 Overview
7.2 Patent Insight

8. Balversa - Comercial Availability, Dosage & Price Analysis

9. Pemazyre - Second Approved FGFR Inhibitor 2020
9.1 Overview
9.2 Patent Insight

10. Pemazyre - Commercial Information
10.1 Dosage & Price Analysis
10.2 Sales Analysis

11. Truseltiq - Third Approved FGFR Inhibitor Drug 2021
11.1 Overview
11.2 Patent Insight

12. Truseltiq - Commercial Availability, Dosage & Price Analysis

13. Global Sales Forecast - 2021 Till 2026
13.1 Belvesra
13.2 Pemazyre
13.3 Truseltiq

14. FGFR Inhibitors - Ongoing Clinical Trials
14.1 By Phase
14.2 By Development Status
14.3 By Region

15. Global - FGFR Inhibitors in Clinical Trials
15.1 Research
15.2 Preclinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-II/III
15.7 Phase-III
15.8 Preregistration

16. Marketed FGFR Inhibitors Drugs Clinical Insight

17. Global FGFR Inhibitors Market Dynamics
17.1 Drivers for Global FGFR Inhibitors Market
17.2 Global FGFR Inhibitors Market Challenges

18. Global FGFR Inhibitors Market Future Outlook

19. Competitive Landscape
19.1 Amgen
19.2 Astex Pharmaceuticals
19.3 AstraZeneca
19.4 Bayer
19.5 Blueprint Medicine
19.6 Boehringer Ingelheim International
19.7 Bristol Mayer Squibb
19.8 Incyte Corporation
19.9 Janssen Pharmaceuticals
19.10 Novartis International
19.11 Pfizer Inc
19.12 Roche
19.13 Taiho
19.14 TransThera Biosciences

List of Tables
Table 6-1: Global - Estimated Adoption Rates for Cholangiocarcinoma Targeting FGFR Inhibitors, 2021-2026
Table 6-2: Global - Estimated Adoption Rates for Cholangiocarcinoma Targeting FGFR Inhibitors, 2021-2026
Table 6-3: Global - Estimated Adoption Rates for NHL Targeting FGFR Inhibitors, 2021-2026
Table 6-4: Global - Estimated Adoption Rates for Lung Cancer Targeting FGFR Inhibitors, 2021-2026


List of Figures
Figure 1-1: History of FGFR Inhibitors

Figure 2-1: General Mechanism of FGFR Inhibitors
Figure 2-2: Balversa - Mechanism of Action Against Urothelial Cancer
Figure 2-3: Mechanism of Pemazyre & Truseltiq Against Cholangiocarcinoma

Figure 3-1: FGFR Mutational Frequency by Cancer Type (%)
Figure 3-2: Roles of FGFR Inhibitors in Cancer
Figure 3-3: Investigational FGFR Inhibitors
Figure 3-4: E7090 Phase II Trial - Study Initiation & Completion Year
Figure 3-5: E7090 Phase II Fortune Trial - Study Initiation & Completion Year
Figure 3-6: E7090 Phase I Trial - Study Initiation & Completion Year
Figure 3-7: Debio 1347 Phase II Trial - Study Initiation & Completion Year
Figure 3-8: Debio 1347 Phase I-II Trial - Study Initiation & Completion Year
Figure 3-9: Futibatinib Phase II Trial - Study Initiation & Completion Year
Figure 3-10: Futibatinib & Pembrolizumab Phase II Trial - Study Initiation & Completion Year
Figure 3-11: Futibatinib & Binimetinib Phase I-II Trial - Study Initiation & Completion Year
Figure 3-12: Futibatinib & Fulvestrant Phase I-II Trial - Study Initiation & Completion Year
Figure 3-13: Rogaratinib Phase II Trial for NSCLC - Study Initiation & Completion Year
Figure 3-14: Rogaratinib Phase II Trial for GIST - Study Initiation & Completion Year
Figure 3-15: Rogaratinib Phase I-II Trial - Study Initiation & Completion Year
Figure 3-16: Rogaratinib Phase I Trial - Study Initiation & Completion Year
Figure 3-17: Derazantinib Phase II Trial - Study Initiation & Completion Year
Figure 3-18: Derazantinib Phase I-II Trial - Study Initiation & Completion Year
Figure 3-19: Derazantinib/Atezolizumab Phase II Trial - Study Initiation & Completion Year
Figure 3-20: RLY4008 Phase I Trial - Study Initiation & Completion Year
Figure 3-21: CPL304110 Phase I Trial - Study Initiation & Completion Year


Figure 4-1: Global - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
Figure 4-2: Global - Number of Cancer Deaths (Million), 2020, 2025 & 2030
Figure 4-3: Global - FGFR Inhibitors Market Opportunity (US$ Million), 2020-2026
Figure 4-4: Global - Cancer Drug Market Opportunity (US$ Billion), 2020-2026
Figure 4-5: Global - FGFR Inhibitors Market by Product (%) 2026

Figure 5-1: US - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
Figure 5-2: US - FGFR Inhibitors Market Opportunity (US$ Million), 2020-2026
Figure 5-3: US - FGFR Inhibitors Market by Product (%) 2026
Figure 5-4: Europe - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
Figure 5-5: Europe - FGFR Inhibitors Market Opportunity (US$ Million), 2021-2026
Figure 5-6: Europe - FGFR Inhibitors Market by Product (%) 2026
Figure 5-7: Japan - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
Figure 5-8: Japan - FGFR Inhibitors Market Opportunity (US$ Million), 2022-2026
Figure 5-9: Japan - FGFR Inhibitors Market by Product (%) 2026
Figure 5-10: ROW - FGFR Inhibitors Market Opportunity (US$ Million), 2022-2026
Figure 5-11: ROW - FGFR Inhibitors Market by Product (%), 2026

Figure 6-1: Global - Number of Cholangiocarcinoma Cases, 2021-2026
Figure 6-2: Global - Cholangiocarcinoma Targeting FGFR Inhibitors Market Opportunity (US$ Million), 2021-2026
Figure 6-3: Global - Number of Urotheluial Carcinoma Cases, 2021-2026
Figure 6-4: Global - Urothelial Carcinoma Targeting FGFR Inhibitors Market Opportunity (US$ Million), 2021-2026
Figure 6-5: Global - Number of NHL Cases, 2021-2026
Figure 6-6: Global - NHL Targeting FGFR inhibitors Market Opportunity (US$ Million), 2023 - 2026
Figure 6-7: Global - Number of Newly Diagnosed Lung Cancer Cases (Million), 2020-2026
Figure 6-8: Global - Lung Cancer Targeting FGFR inhibitors Market Opportunity (US$ Million), 2022 - 2026

Figure 7-1: Balversa - Patent Issue & Expiration Year


Figure 8-1: Balversa - Price for 56 Tablets Supply & Price per Unit of 3mg Tablet (US$), July'2021
Figure 8-2: Balversa - Price for 84 Tablets Supply & Price per Unit of 3mg Tablet (US$), July'2021
Figure 8-3: Balversa - Price for 28 Tablets Supply & Price per Unit of 4mg Tablet (US$), July'2021
Figure 8-4: Balversa - Price for 56 Tablets Supply & Price per Unit of 4mg Tablet (US$), July'2021
Figure 8-5: Balversa - Price for 28 Tablets Supply & Price per Unit of 5mg Tablet (US$), July'2021
Figure 8-6: Balversa - Initial & Maintenance Dose (mg/Day)
Figure 8-7: Balversa - Initial Dose After Reduction (mg/Day)
Figure 8-8: Balversa - Maintenance Dose After Reduction (mg/Day)

Figure 9-1: Pemazyre - Approval Year by Region
Figure 9-2: Pemazyre - Patent Issue & Expiration Year

Figure 10-1: US - Price for 14 Tablets Supply & Price per Unit of Various Doses of Pemazyre (US$), July'2021
Figure 10-2: Europe - Price for 14 Tablets Supply & Price per Unit of Various Doses of Pemazyre (US$), July'2021
Figure 10-3: Pemazyre - Duration of Single Treatment Cycle by Phase (days)
Figure 10-4: Pemazyre - Initial & Reduced Dose (mg/day)
Figure 10-5: Global - Pemazyre Quarterly Sales (US$ Million), 2020

Figure 11-1: Truseltiq - FDA Approval & Orphan Designation Year
Figure 11-2: Truseltiq - Patent Issue & Expiration Year

Figure 12-1: Truseltiq - Price for 42 Capsules Supply & Price per Unit of Dose 125mg (US$), August'2021
Figure 12-2: Truseltiq - Price for 42 Capsules Supply & Price per Unit of Dose 50mg (US$), August'2021
Figure 12-3: Truseltiq - Price for 63 Capsules Supply & Price per Unit of Dose 75mg (US$), August'2021


Figure 12-4: Truseltiq - Price for 21 Capsules Supply & Price per Unit of Dose 100mg (US$), August'2021
Figure 12-5: Truseltiq - Duration of Single Treatment Cycle by Phase (days)
Figure 12-6: Truseltiq - Initial & Reduced Dose (mg/day)

Figure 13-1: Global - Balversa Sales Forecast (US$ Million), 2021-2026
Figure 13-2: US - Balversa Sales Forecast (US$ Million), 2021-2026
Figure 13-3: Europe - Balversa Sales Forecast (US$ Million), 2022-2026
Figure 13-4: Japan - Balversa Sales Forecast (US$ Million), 2022-2026
Figure 13-5: ROW - Balversa Sales Forecast (US$ Million), 2022-2026
Figure 13-6: Global - Pemazyre Sales Forecast (US$ Million), 2021-2026
Figure 13-7: US - Pemazyre Sales Forecast (US$ Million), 2021-2026
Figure 13-8: Europe - Pemazyre Sales Forecast (US$ Million), 2022-2026
Figure 13-9: Japan - Pemazyre Sales Forecast (US$ Million), 2022-2026
Figure 13-10: ROW - Pemazyre Sales Forecast (US$ Million), 2022-2026
Figure 13-11: Global - Truseltiq Sales Forecast (US$ Million), 2021-2026
Figure 13-12: US - Truseltiq Sales Forecast (US$ Million), 2021-2026
Figure 13-13: Europe - Truseltiq Sales Forecast (US$ Million), 2022-2026
Figure 13-14: Japan - Truseltiq Sales Forecast (US$ Million), 2022-2026
Figure 13-15: ROW - Truseltiq Sales Forecast (US$ Million), 2022-2026

Figure 14-1: Pemazyre - Number of Clinical Trials by Phase, July'2021
Figure 14-2: Pemazyre - Number of Clinical Trials by Phase, July'2021
Figure 14-3: Pemazyre - Number of Clinical Trials by Development Status, July'2021
Figure 14-4: Pemazyre - Number of Clinical Trials by Development Status (%), July'2021
Figure 14-5: Pemazyre - Number of Clinical Trials by Region, July'2021

Figure 15-1: Global - Number of FGFR Inhibitors Drugs in Clinical Trials by Phase, 2021 till 2026
Figure 15-2: Global - Number of FGFR Inhibitors Drugs in Clinical Trials by Company, 2021 till 2026
Figure 15-3: Global - Number of FGFR Inhibitors Drugs in Clinical Trials by Patient Segment, 2021 till 2026


Figure 15-4: Global - Number of FGFR Inhibitors Drugs in Clinical Trials by Country, 2021 till 2026

Figure 17-1: Global FGFR Market Drivers
Figure 17-2: Challenges for Global FGFR Inhibitors Market
Figure 17-3: US - Annual Treatment Cost Comparison Using Various Drugs (US$), August'2021


Companies Mentioned
. Amgen
. Astex Pharmaceuticals
. AstraZeneca
. Bayer
. Blueprint Medicine
. Boehringer Ingelheim International
. Bristol Mayer Squibb
. Incyte Corporation
. Janssen Pharmaceuticals
. Novartis International
. Pfizer
. Roche
. Taiho
. TransThera Biosciences
.